Markt geschlossen· · CNY · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China's National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine market. This marks Lupin's first product entry into China — a significant milestone in its global expansion.
As Asian markets stabilize following strong economic data and limited new catalysts, investors are increasingly eyeing dividend stocks as a reliable source of income amid global uncertainties. In such an environment, a good dividend stock is often characterized by consistent payouts and the potential for steady growth, making them appealing to those seeking stability in their investment portfolios.
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.